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Antiﬁbrinolytic Proteins
Are Found in Plasma of
Older Octogenarians With
Cardiovascular Disease
and Cognitive DeclineAging is one of the most important contributors
to cardiovascular disease (CVD). Moreover, aging and
CVD are important triggers of cognitive decline in older
people (1). However, there is little understanding of
themolecular effectors contributing to this age-related
atherothrombotic risk and cognitive decline and
their association with healthy longevity in the elderly.
For this reason, we have investigated the plasma pro-
teome in octogenarians in relation with cognitive
decline and ischemic atherothrombotic disease.
A total of 100 community-dwelling octogenarians
(age 87  0 years) from the OCTABAIX (Oldest Char-
acTheristic and Assessments-Baix Llobregat) study (2)
were included. Functional (Barthel, Lawton-Brody),
cognitive (MEC [Spanish version of the Mini-Mental
State Examination]) and mini-nutritional assessment
(MNA) results were recorded. The differential plasma
proteomic signature was investigated as previously
reported (3) in 2 groups of subjects: 1) healthy octoge-
narians (HO) (preserved functional, cognitive, and
nutritional status) without any previous clinical
manifestation of CVD (n ¼ 10); and 2) unhealthy octo-
genarians (UHO) with cognitive decline (MEC <24),
functional dependency (Barthel <90), and malnutri-
tion (MNA <23.5) who had had a previous cardiovas-
cular ischemic event (acute myocardial infarction
and/or stroke) and were treated to guidelines (n ¼ 8).
Enzyme-linked immunosorbent assay validation was
performed in 100 subjects: 38 HO, 27 UHO, and 35
HO with a previous cardiovascular ischemic event
(HO-CVD). Fibrin clot formation/lysis was tested by
confocal microscopy. The “IDIAP-Jordi Gol” Ethics
Committee approved the project, and it was conduct-
ed according to the principles of Helsinki’s Declara-
tion, with written informed consent. The statistical
analysis was performed according to the sample sizeand the dataset distribution in each case. A p value
#0.05 (2-sided test) was considered signiﬁcant.
Alpha-2-antiplasmin (A2AP) (p ¼ 0.008) and coag-
ulation factor XIII B-chain (FXIIIB) (p ¼ 0.012) were
increased in the plasma proteome of UHO patients
when compared with HO individuals (Figure 1A), and
were positively correlated (rho ¼ 0.732; p ¼ 0.005),
highlighting a coordinated increase in the anti-
ﬁbrinolytic pathway (Figure 1B). FXIIIB was inversely
correlated with MNA (rho ¼ 0.588; p ¼ 0.019) and
Lawton-Brody (rho ¼ 0.544; p ¼ 0.03), which has
been reported to be an independent predictor of 3-year
mortality (3).
Validation studies (enzyme-linked immunosorbent
assay) conﬁrmed the proteomic results. A2AP levels
were lower in HO than in HO-CVD (p ¼ 0.038) and
UHO subjects (p ¼ 0.032) (Figure 1C). FXIII levels were
also lower in HO subjects than in UHO (p ¼ 0.008)
(Figure 1C) but not HO-CVD subjects. Subjects without
CVD had lower A2AP levels than those who experi-
enced CVD (p ¼ 0.014). Whereas those with preserved
cognitive, functional, and nutritional status (inde-
pendently of CVD) showed decreased FXIII levels
compared with UHO subjects (p ¼ 0.01). Patients with
cognitive decline (MEC <24) showed higher FXIII
levels (p ¼ 0.04). In multivariate analysis, including
pharmacological treatment, only FXIII and A2AP
levels remained as independent predictors of un-
healthy phenotype and CVD.
Plasma from UHO patients formed clots with larger
ﬁber diameter (p ¼ 0.0002) and decreased pore size
(p ¼ 0.0007) (Figure 1D), resulting in a tighter ﬁbrin
network (Figure 1E) with a slower ﬁbrinolytic rate
(135 mm/h) than those from HO individuals (232 mm/h).
Genetic testing showed that the healthy phenotype
was not associated with any polymorphism detected
in the FXIIIB gene.
In the present study, we have identiﬁed a coordi-
nated decrease in plasma levels of 2 antiﬁbrinolytic
proteins, A2AP and FXIII, in HO subjects without
any previous episode of CVD, suggesting that
an active spontaneous ﬁbrinolysis protects against
CVD and cognitive impairment. A2AP is the main
serine-protease inhibitor controlling the dissolution
of ﬁbrin polymers by inhibiting plasmin activity
(4). Coagulation factor XIII cross-links A2AP into
the ﬁbrin network and promotes intramolecular
FIGURE 1 Plasma Proteomic Proﬁle Analysis: HO Versus UHO
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2668cross-links between ﬁbrin strands, forming stable
clots with an increased ﬁber density and a decreased
proteolytic vulnerability (5). Thus, our confocal stu-
dies have revealed that increased levels of anti-
ﬁbrinolytic proteins in UHO with a previous CVD
event are associated with the formation of denser
ﬁbrin clots with a decreased ﬁbrinolytic response.
Interestingly, we have found that changes in FXIII
are associated with cognitive status in the elderly,
whereas changes in A2AP are associated with CVD
event presentation, highlighting that the combination
of both proteins could provide information about
the global health status in the elderly.
In conclusion, the coordinated increase in anti-
ﬁbrinolytic proteins induces a phenotype with
reduced spontaneous ﬁbrinolysis and, hence, a di-
minished capability for spontaneous thrombus res-
olution in octogenarians with cognitive decline,CVD, and unhealthy longevity. Further studies are
warranted to longitudinally analyze the effect of
these antiﬁbrinolytic markers in the aging process.Judit Cubedo, PhD
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Are Associated With
All-Cause Mortality and
Cardiovascular Outcomes
in the General PopulationIndividuals with systemic autoimmune disease
exhibit a heightened risk for cardiovascular disease
(CVD) (1). Antinuclear autoantibodies (ANA) have
been reported in approximately 25% of the general
population (2); yet, only a small fraction of those in-
dividuals will develop autoimmune disease. The sig-
niﬁcance of this “benign autoimmunity” is unknown,
and the role of ANA as a cardiovascular risk factor in
the general population has not been clearly deﬁned.
We examined the associations among ANA and
all-cause mortality and cardiovascular events in the
DHS (Dallas Heart Study), a multiethnic, population-
based, cohort study (2,3).
The study population included 2,803 participants
who were free of CVD, had no self-reported autoim-
mune disease with use of an immunosuppressive
medication, and had complete follow-up for events
through December 2010. Plasma ANA were measured
at baseline using an enzyme-linked immunosorbent
assay (Inova, San Diego, California) and reported
as enzyme-linked immunosorbent assay units (EU)
(2). HEp2-cell indirect immunoﬂuorescence (IF) is
used more commonly in clinical practice; however,
we have previously reported a high correlation ofANA EU with immunoﬂuorescence titers (r ¼ 0.8;
p ¼ 0.02) (2).
Mortality data were queried from the National
Death Index through 2010. Atherosclerotic cardio-
vascular disease (ASCVD) events were adjudicated,
and included cardiovascular death, myocardial in-
farction, coronary revascularization, and stroke (3).
Associations of log-transformed ANA with all-cause
mortality, cardiovascular death, and ASCVD were
assessed by Cox proportional hazards regression,
adjusting for: 1) age, race/ethnicity, and sex; and
2) model 1 plus hypertension, diabetes, smoking,
body mass index, estimated glomerular ﬁltration
rate, statin use, total cholesterol, triglycerides, and
high-density lipoprotein cholesterol. Sensitivity
analyses excluded participants with an ANA >65 EU
(n ¼ 150).
Participants with higher ANA were more likely to
be female and African-American (p < 0.0001 for
each). Higher ANA were seen in participants with
hypertension (p ¼ 0.02) and in nonsmokers
(p < 0.0001). We did not ﬁnd differences in ANA on
the basis of age, diabetes, hypercholesterolemia, and
metabolic syndrome.
Over a median 9.4-year follow-up, 158 total deaths,
54 cardiovascular deaths, and 157 ASCVD events
were recorded. After adjusting for age, sex, and
race/ethnicity, higher ANA were associated with all-
cause mortality (hazard ratio [HR] per 1 SD of log
[ANA]: 1.27; 95% conﬁdence interval [CI]: 1.10 to 1.46;
p ¼ 0.0008), cardiovascular death (HR: 1.42; 95% CI:
1.13 to 1.77; p ¼ 0.002), and ASCVD (HR: 1.17; 95% CI:
1.01 to 1.35; p ¼ 0.04) (Table 1). ANA remained inde-
pendently associated with all-cause mortality, car-
diovascular death, and ASCVD after adjustment for
CVD risk factors. The associations of ANA with
all-cause and cardiovascular death remained signiﬁ-
cant after excluding participants with ANA >65 EU
(immunoﬂuorescence titer of 1:160).
The major ﬁnding of this study is that higher ANA
are independently associated with all-cause mortal-
ity, cardiovascular death, and ASCVD in an ethnically
diverse, community-based population. Importantly,
these associations are evident at ANA levels below
those traditionally considered to be indicative of
autoimmune disease.
A limited number of studies have investigated as-
sociations of low-level autoimmunity with CVD (4,5).
Liang et al. (5) found that ANA positivity was associ-
ated with cardiovascular events and mortality after
adjusting for cardiovascular risk factors and autoim-
mune disease. However, ANA were measured for
clinical purposes, resulting in a prevalence of auto-
immune disease that was 10-fold higher than in the
